{"id":"W4401114827","doi":"10.1007/s13555-024-01224-x","title":"Deucravacitinib Improves Patient-Reported Outcomes in Patients with Moderate to Severe Psoriasis: Results from the Phase 3 Randomized POETYK PSO-1 and PSO-2 Trials","year":2024,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":7,"is_retracted":false,"has_abstract":true,"ca_institutions":"Probity Medical Research; University of Toronto","funders":"Janssen Biotech; LEO Pharma; Regeneron Pharmaceuticals; Sun Pharma; Bristol-Myers Squibb; Eli Lilly and Company; Ortho Dermatologics; Incyte; Dermira; Celgene; Sanofi; Amgen; Pfizer","keywords":"Randomized controlled trial; Psoriasis; Medicine; Phase (matter); Physical therapy; Internal medicine; Dermatology; Physics","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002982721,0.0006657654,0.001402668,0.0002043699,0.0002846292,0.0008216266,0.0004787098,0.0008402638,0.00228866],"category_scores_gemma":[0.002378907,0.0002609459,0.001986268,0.0003223148,0.0004428833,0.0004880906,0.0002394573,0.001549559,0.0002621613],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004700883,"about_ca_system_score_gemma":0.0006691617,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004571775,"about_ca_topic_score_gemma":0.001428187,"domain_scores_codex":[0.9988298,0.0007065798,0.0001023392,0.0001402113,0.0001329057,0.00008831805],"domain_scores_gemma":[0.9983012,0.0005709341,0.0005992583,0.0001038364,0.0001243287,0.0003004411],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8570671,0.008876042,0.01039864,0.002288691,0.005755906,0.0001101579,0.0001237456,0.0009029802,0.01284958,0.0001217471,0.002865082,0.09864028],"study_design_scores_gemma":[0.770689,0.1631744,0.05538509,0.0001822239,0.00370302,0.0005204529,0.0000651765,0.0008220359,0.002278297,0.0002579025,0.002876109,0.00004619124],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9773132,0.017789,0.0004028113,0.000580475,0.000132649,0.0009398131,0.0008018335,0.00006164735,0.001978646],"genre_scores_gemma":[0.9928613,0.004094219,0.0005706616,0.0004944112,0.0001785755,0.0005139752,0.00086754,0.000008862754,0.0004104395],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002982721,"threshold_uncertainty_score":0.01577431,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02085379842455284,"score_gpt":0.2720310845102961,"score_spread":0.2511772860857432,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}